Department of General and Emergency Surgery, Misericordia Hospital, Azienda Usl Toscana Sud Est. School of Robotic Surgery, Grosseto, Italy.
Medical Oncology Unit, Misericordia Hospital, Grosseto, Italy.
Surg Oncol. 2023 Apr;47:101907. doi: 10.1016/j.suronc.2023.101907. Epub 2023 Feb 2.
This Italian multicentric retrospective study aimed to investigate the possible changes in outcomes of patients undergoing surgery for gastrointestinal cancers during the COVID-19 pandemic.
Our primary endpoint was to determine whether the pandemic scenario increased the rate of patients with colorectal, gastroesophageal, and pancreatic cancers resected at an advanced stage in 2020 compared to 2019. Considering different cancer staging systems, we divided tumors into early stages and advanced stages, using pathological outcomes. Furthermore, to assess the impact of the COVID-19 pandemic on surgical outcomes, perioperative data of both 2020 and 2019 were also examined.
Overall, a total of 8250 patients, 4370 (53%) and 3880 (47%) were surgically treated during 2019 and 2020 respectively, in 62 Italian surgical Units. In 2020, the rate of patients treated with an advanced pathological stage was not different compared to 2019 (P = 0.25). Nevertheless, the analysis of quarters revealed that in the second half of 2020 the rate of advanced cancer resected, tented to be higher compared with the same months of 2019 (P = 0.05). During the pandemic year 'Charlson Comorbidity Index score of cancer patients (5.38 ± 2.08 vs 5.28 ± 2.22, P = 0.036), neoadjuvant treatments (23.9% vs. 19.5%, P < 0.001), rate of urgent diagnosis (24.2% vs 20.3%, P < 0.001), colorectal cancer urgent resection (9.4% vs. 7.37, P < 0.001), and the rate of positive nodes on the total nodes resected per surgery increased significantly (7 vs 9% - 2.02 ± 4.21 vs 2.39 ± 5.23, P < 0.001).
Although the SARS-CoV-2 pandemic did not influence the pathological stage of colorectal, gastroesophageal, and pancreatic cancers at the time of surgery, our study revealed that the pandemic scenario negatively impacted on several perioperative and post-operative outcomes.
本项意大利多中心回顾性研究旨在探讨 COVID-19 大流行期间胃肠道癌症患者手术治疗结果的可能变化。
我们的主要终点是确定 2020 年与 2019 年相比,接受结直肠、胃食管和胰腺癌症切除术的患者中晚期癌症的比例是否增加。考虑到不同的癌症分期系统,我们根据病理结果将肿瘤分为早期和晚期。此外,为评估 COVID-19 大流行对手术结果的影响,我们还检查了 2020 年和 2019 年的围手术期数据。
共有 8250 名患者,62 个意大利外科单位中分别有 4370 名(53%)和 3880 名(47%)患者于 2019 年和 2020 年接受手术治疗。2020 年,接受晚期病理分期治疗的患者比例与 2019 年无差异(P=0.25)。然而,季度分析显示,2020 年下半年接受晚期癌症切除的比例有高于 2019 年同期的趋势(P=0.05)。在大流行期间,癌症患者的 Charlson 合并症指数评分(5.38±2.08 比 5.28±2.22,P=0.036)、新辅助治疗(23.9%比 19.5%,P<0.001)、紧急诊断率(24.2%比 20.3%,P<0.001)、结直肠癌紧急切除术(9.4%比 7.37%,P<0.001)以及手术切除的总淋巴结阳性率均有显著增加(7%比 9%,2.02±4.21 比 2.39±5.23,P<0.001)。
尽管 SARS-CoV-2 大流行并未影响手术时结直肠、胃食管和胰腺癌症的病理分期,但我们的研究表明,大流行对围手术期和术后的多项结果产生了负面影响。